Do you really think that the white coats are going to tell you the truth about EDTA chelation when it completely destroys their pitch for $50,000 to $100,000 surgeries? Seriously, would they kill a yearly multi-billion dollar cash cow to save you time, money and pain? Do you think they really want to cure you? How would they buy their million dollar homes, cars, expensive vacations, etc?
By the way should you buy something from an Amazon link on this site I'll make a whopping 1%. That means if the product costs $40 I'll get $.40! 40 CENTS! I'm gonna be rich LOLOLOL.
The Landmark TACT Trial
In 2013, the National Institutes of Health (NIH) conducted the groundbreaking Trial to Assess Chelation Therapy (TACT), which produced surprising results. The JAMA study revealed that EDTA chelation "modestly reduced the risk of adverse cardiovascular outcomes" in patients with previous myocardial infarction.
Key Findings of the Original TACT Trial
According to the National Center for Complementary and Integrative Health, participants receiving chelation therapy experienced:
- An 18 percent reduced risk of subsequent cardiac events
- Reduced risk of heart attack, stroke, and hospitalization for angina
The TACT2 Follow-Up Study
The follow-up study, TACT2, was specifically designed to investigate these initial findings, particularly in patients with diabetes and a history of heart attack. A 2024 JAMA publication reported more complex results:
Nuanced Outcomes
- The clinical benefits found in the earlier TACT trial were not fully replicated
- The results did not conclusively support widespread clinical use of EDTA chelation
Mechanistic Insights
Researchers hypothesized that EDTA might work by:
- Removing calcium from arterial plaques
- Reducing inflammatory markers
- Chelating heavy metals that contribute to cardiovascular disease
The American College of Cardiology notes that the original TACT trial demonstrated "a modest reduction in death and cardiovascular events associated with EDTA."
Metal Reduction and Physiological Effects
An interesting finding from the trials was the significant impact on metal levels. A 2024 environmental health study found that participants receiving chelation therapy:
- Experienced a 61% drop in blood lead levels
- Showed changes in other metal concentrations in blood and urine
Critical Considerations
While the results are intriguing, experts urge caution:
Potential Benefits
- Modest reduction in cardiovascular events
- Potential heavy metal detoxification
Limitations and Risks
- Not FDA-approved for cardiovascular treatment
- Potential kidney damage
- Significant cost ($75-$125 per treatment)
- Possible interference with standard medical treatments
The Scientific Consensus
A systematic review in the American Heart Association's journal suggests that while intriguing, more research is needed to definitively establish EDTA's cardiovascular benefits.
Practical Takeaways
- EDTA shows promise but is not a proven cardiovascular treatment
- Always consult healthcare professionals
- Do not replace standard medical treatments
- Consider EDTA only under strict medical supervision
Future Research
The TACT2 investigators anticipate that continued research might provide more definitive insights into EDTA's potential therapeutic mechanisms.
Conclusion
The story of EDTA is a reminder of science's complexity. What initially seemed like a breakthrough treatment has proven to be a nuanced, ongoing area of investigation. The trials demonstrate the importance of rigorous, repeated scientific examination.
